Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Vinorelbine and Docetaxel in Advanced NSCLC
NCT00026156Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2001
- Primary completion
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and docetaxel in non-small cell lung cancer (NSCLC), sponsored by SWOG Cancer Research Network. Primary endpoints: Overall Survival up to 3 years and Objective Tumor Response Rate up to 3 years. Started Nov 2001; status: completed.
02
Drugs
vinorelbinedocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00026156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026156.